LCD-DL40140
Document details
Summary
The proposed Local Coverage Determination (LCD) for molecular testing related to solid organ allograft rejection could significantly influence billing practices for relevant tests. With proper coding,Impact of new LCD on organ transplant testing reimbursement.
Affected specialty
Clinical Laboratory alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=40139&ver=7CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy CMS-T-R13849CP · Clinical Laboratory
CMS is updating the Laboratory NCD Edit Software effective October 5, 2026, to reflect changes in National Coverage Determinations for lab services. Billing teams must review updated NCD edits in thei
View alertPolicy CMS-T-R13855CP · Clinical Laboratory
This transmittal implements the July 2026 quarterly update to the Clinical Laboratory Fee Schedule (CLFS), effective July 6, 2026. Billing teams must update their lab fee schedule tables to reflect th
View alertPolicy LCD-L39044 · Clinical Laboratory
The LCD L39044 focuses on coverage for molecular syndromic panels for infectious disease pathogen identification. As a final LCD, it is currently active and will be effective starting June 25, 2026, i
View alertPolicy LCD-L40272 · Clinical Laboratory
LCD L40272 establishes coverage criteria for MolDX biomarker testing in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), ef
View alert